COMPARE · Reviewed July 9, 2026
ANIP vs DOCS
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 83.7, DOCS scored 90.2 — DOCS leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
83.7
$83.78 · $1.9B
Score gap
6.5
DOCS leads
DOCS
Doximity, Inc.
90.2
$22.01 · $4.0B
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
DOCS
64
Qualityreturns · margins · balance sheet
90
100
Growthrevenue & earnings expansion
93
91
Valuevaluation vs sector peers
88
ANIP is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
DOCS
$191mC
FCF
$326mC
+43.8%A
Rev
+13.1%B+
1.12C
D/E
0.01A
21.4xB+
P/E
22.5xB+
0.49A
PEG
0.59A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
DOCS
47% below
Price vs fair valuelower is cheaper
14% below
+64%
1-yr DCF upside
+5%
+89%
5-yr DCF upside
+16%
+132%
10-yr DCF upside
+33%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
DOCS
Why this score
- Durable high returns
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.9b. 16% off the 52-week high of $99.50. Revenue growing +44% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $112.71 (implying +35% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
DOCSDoximity, Inc.
Why now
Health Information Services · market cap $4.0b. Down 71% from 52-week high of $76.51 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $24.53 (implying +11% upside).
Moat
Net margin 30% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 167% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 71% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.